Jonathan Wolleben
Stock Analyst at Citizens
(4.67)
# 191
Out of 5,106 analysts
233
Total ratings
56.96%
Success rate
32.21%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $141 → $167 | $113.56 | +47.06% | 6 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $87 → $120 | $67.06 | +78.94% | 11 | Dec 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $6.23 | +461.80% | 9 | Nov 14, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $11 → $10 | $6.92 | +44.51% | 10 | Nov 13, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $254 → $259 | $83.40 | +210.55% | 9 | Nov 11, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $16.91 | +65.58% | 6 | Nov 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $69 → $102 | $95.35 | +6.97% | 13 | Nov 7, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $143 → $108 | $50.49 | +113.90% | 17 | Nov 7, 2025 | |
| ALT Altimmune | Maintains: Market Outperform | $15 → $14 | $5.27 | +165.65% | 14 | Nov 7, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Market Outperform | $27 → $25 | $7.57 | +230.25% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $485 → $527 | $571.44 | -7.78% | 14 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $81 → $95 | $65.00 | +46.15% | 12 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $8.87 | +125.48% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.93 | - | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $14.56 | +99.18% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $4.05 | +344.44% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $24.16 | +115.23% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $8 | $4.22 | +89.57% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.33 | +243.35% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $18.39 | +14.19% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.09 | +1,276.15% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.54 | +190.52% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $29.86 | +27.26% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $43.99 | +13.66% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $68.23 | +31.91% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $128.39 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $597.80 | -18.87% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.73 | +992.90% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $27.79 | -13.64% | 1 | May 12, 2023 |
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Market Outperform
Price Target: $141 → $167
Current: $113.56
Upside: +47.06%
Structure Therapeutics
Dec 12, 2025
Maintains: Market Outperform
Price Target: $87 → $120
Current: $67.06
Upside: +78.94%
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $6.23
Upside: +461.80%
Savara
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $6.92
Upside: +44.51%
Spruce Biosciences
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $83.40
Upside: +210.55%
KalVista Pharmaceuticals
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $16.91
Upside: +65.58%
Protagonist Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $69 → $102
Current: $95.35
Upside: +6.97%
Crinetics Pharmaceuticals
Nov 7, 2025
Maintains: Market Outperform
Price Target: $143 → $108
Current: $50.49
Upside: +113.90%
Altimmune
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $5.27
Upside: +165.65%
BioCryst Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $7.57
Upside: +230.25%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $485 → $527
Current: $571.44
Upside: -7.78%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $81 → $95
Current: $65.00
Upside: +46.15%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $8.87
Upside: +125.48%
Oct 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $12.93
Upside: -
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $14.56
Upside: +99.18%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $4.05
Upside: +344.44%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $24.16
Upside: +115.23%
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $4.22
Upside: +89.57%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.33
Upside: +243.35%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $18.39
Upside: +14.19%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.09
Upside: +1,276.15%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.54
Upside: +190.52%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $29.86
Upside: +27.26%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $43.99
Upside: +13.66%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $68.23
Upside: +31.91%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $128.39
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $597.80
Upside: -18.87%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.73
Upside: +992.90%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $27.79
Upside: -13.64%